06 Dec 2022 Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement Launch fueled by syndicate of blue-chip investors co-led by Qiming Venture Partners USA and venBio Partners Company’s proprietary end-to-end Encompass™ platform designs enhancement-targeting chimeric (ENTAC™) molecules Founding team ...
